Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | ARNT | P27540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086930 | 0.94 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19KCNH2CAMK2A | |
| SCHEMBL1343826 | 0.91 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL3220100 | 0.90 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL3982722 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19KCNH2CAMK2A | |
| SCHEMBL4752470 | 0.89 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2CAMK2A | |
| SCHEMBL16175471 | 0.89 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2CAMK2A | |
| SCHEMBL1344803 | 0.89 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19KCNH2CAMK2A | |
| SCHEMBL16175755 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19KCNH2THRA | |
| SCHEMBL4754828 | 0.87 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL1344591 | 0.87 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063028-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157273-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157273-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, REV1 | CYP3A4 889/4885CYP2C9 1726/4885CYP2C19 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.